State Street SPDR S&P Biotech ETF
292 hedge funds and large institutions have $3.09B invested in State Street SPDR S&P Biotech ETF in 2017 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 100 increasing their positions, 78 reducing their positions, and 48 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
9.07% more ownership
Funds ownership: 88.91% → 97.98% (+9.1%)
7% more funds holding
Funds holding: 274 → 292 (+18)
45% less call options, than puts
Call options by funds: $656M | Put options by funds: $1.19B
Holders
292
Holding in Top 10
12
Calls
$656M
Puts
$1.19B
Top Buyers
| 1 | +$155M | |
| 2 | +$116M | |
| 3 | +$112M | |
| 4 |
AssetMark Inc
Concord,
California
|
+$95.4M |
| 5 |
Citigroup
New York
|
+$70.4M |
Top Sellers
| 1 | -$72.4M | |
| 2 | -$33.2M | |
| 3 | -$29.9M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22.3M |
| 5 |
Parallax Volatility Advisers
San Francisco,
California
|
-$21.4M |